DRKS00017037Recruiting未知
A randomised, double-blind, placebo-controlled study on the impact of doxycycline on aversive memory in healthy individuals - DoxAv
Department of Psychiatry, Psychotherapy, Psychosomatics, University of Zurich0 sites560 target enrollmentStarted: November 5, 2019Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Sponsor
- Enrollment
- 560
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized controlled study
- Masking
- Blinded (masking used)
Eligibility Criteria
- Ages
- 18 Years to 40 Years (—)
- Sex
- All
Inclusion Criteria
- •Informed Consent as documented by signature
- •- Age 18 – 40 years
Exclusion Criteria
- •Allergy to doxycycline or to any other ingredient in the named drugs
- •Use of any drugs in the 2 weeks prior to the study with the exception of contraceptive drugs and incidental use of NSARs or paracetamol
- •Women who are pregnant or breast feeding,
- •Intention to become pregnant during the course of the study,
- •Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration
- •Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.)
- •Any history of psychiatric, neurological, addiction, or systemic/rheumatic disease
- •Known or suspected non-compliance, drug or alcohol abuse
- •Inability to follow the procedures of the study, e.g. due to language problems
- •Participation in another study with investigational drug within 30 days preceding and during the present study,
- •Previous enrolment into the current study,
- •Members of the study team and their family members and dependants
- •Regular work in a medical profession
- •Life time history of being a victim of interpersonal violence or other potentially traumatic experience, or close relative of a person with such history
Investigators
Similar Trials
Completed
Not Applicable
A randomised, double-blind, placebo-controlled study evaluating Palmitoylethanolamide for diabetic-related peripheral neuropathic pain, inflammation and quality of lifediabetic-related peripheral neuropathyMetabolic and Endocrine - DiabetesNeurological - Other neurological disordersACTRN12620001302943Gencor Pacific Ltd70
Active, not recruiting
Phase 1
Study to evaluate the micro-macroscopic effects on muscles, the safety and tolerability, and the efficacy of givinostat in patients with Becker Muscular DystrophyEUCTR2017-001629-41-NLITALFARMACO S.P.A.48
Active, not recruiting
Not Applicable
A randomised, double-blind, placebo-controlled study to evaluate the transthoracic Doppler echocardiography method as a non-invasive method for coronary function measurements; ability to detect short-term statin effects in patients with increased cardiovascular riskEUCTR2008-002332-15-SEAstraZeneca AB
Active, not recruiting
Phase 1
Clinical trial to study the safety and tolerability of EP395 in comparison with placebo in patients with chronic obstructive pulmonary disease (COPD)Chronic obstructive pulmonary disease (COPD)MedDRA version: 21.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2021-005787-22-DEEpiEndo Pharmaceuticals60
Active, not recruiting
Phase 1
A study to test a potential new treatment for COPD patients suffering from the common cold or influenza.Patients with Chronic Obstructive Pulmonary Disease (COPD). In part 1 of the study the patients are in stable state. In part 2 of the study patients have a respiratory virus infection (i.e. cold or flu virus).MedDRA version: 21.1 Level: LLT Classification code 10010953 Term: COPD exacerbation System Organ Class: 100000004855EUCTR2017-003679-75-GBSynairgen Research Limited130